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 ABSTRACT 
The development of high-resolution nanosized photoacoustic contrast agents
is an exciting yet challenging technological advance. Herein, antibody (breast
cancer-associated antigen 1 (Brcaa1) monoclonal antibody)- and peptide (RGD)-
functionalized gold nanoprisms (AuNprs) were used as a combinatorial
methodology for in situ photoacoustic imaging, angiography, and localized 
hyperthermia using orthotopic and subcutaneous murine gastric carcinoma 
models. RGD-conjugated PEGylated AuNprs are available for tumor angiography,
and Brcaa1 monoclonal antibody-conjugated PEGylated AuNprs are used for 
targeting and for in situ imaging of gastric carcinoma in orthotopic tumor models.
In situ photoacoustic imaging allowed for anatomical and functional imaging at
the tumor site. In vivo tumor angiography imaging showed enhancement of the
photoacoustic signal in a time-dependent manner. Furthermore, photoacoustic 
imaging demonstrated that tumor vessels were clearly damaged after localized
hyperthermia. This is the first proof-of-concept using two AuNprs probes as 
highly sensitive contrasts and therapeutic agents for in situ tumor detection and 
inhibition. These smart antibody/peptide AuNprs can be used as an efficient 
nanotheranostic platform for in vivo tumor detection with high sensitivity, as well as
for tumor targeting therapy, which, with a single-dose injection, results in tumor
size reduction and increases mice survival after localized hyperthermia treatment.
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1 Introduction 
Since Richard Feynman’s famous talk, “There's plenty 
of room at the bottom” at an American Physical Society 
meeting at Caltech in 1959 [1], nanotechnology has led 
to the development of new materials (e.g. nanoparticles 
(NPs)) and devices [2] with a wide-range of appli-
cations, especially in imaging, diagnostics, and therapy, 
contributing to the early detection and treatment of 
cancer and metastasis [3, 4]. NPs are within the same 
size domain as many biomolecules, including enzymes, 
antibodies, and protein receptors. This, combined with 
the unique properties of materials in the nanosize 
range, provides scope for improved biomaterials for 
therapy and diagnostics. 
Since light absorption from biological tissue com-
ponents is minimized at near-infrared (NIR) wavelengths, 
most NPs for in vivo imaging have been designed to 
strongly absorb in the NIR region so as to be effective 
contrast agents [5, 6]. Gold-nanoprisms (AuNprs) have 
been extensively used in bioimaging owing to their 
ability to tune the plasmon resonance maximum further 
into the NIR region [7, 8]. More recently, Bao et al. 
reported the use of AuNprs as a novel contrast agent 
for the hybrid technique of photoacoustic imaging 
(PAI). The authors demonstrated an in silico electron 
tomographic reconstruction of such Au nanostructures, 
which showed promise for application in biomedical 
imaging, drug delivery, and photothermal therapy [9]. 
Light, as an electromagnetic wave, possesses the 
property of diffraction and diffusion, which inevitably 
confines its application in bioimaging of tumors. 
Localized imaging with both deep penetration and high 
resolution is still a challenge for other modalities such 
as optical imaging and ultrasound imaging. In PAI, a 
pulse of NIR laser light is used in resonance with the 
surface plasmon instead of a continuous NIR source. 
This technique causes rapid thermal expansion of the 
surrounding media and the generation of a sound wave 
that can be detected on the surface of the subject. The 
use of NIR reduces the amount of absorption that 
occurs by the light, however absorption of the light 
by various other organs is unavoidable [10]. 
Numerous systems using Au nanocages [11] or  
Au nanorods [12, 13] have been used as NIR contrast- 
enhancing agents for photoacoustic tomography and 
to image their distribution when circulating in the 
vasculature of mice tissues, as well as to enhance the 
diagnostic power of optoacoustic imaging. Nevertheless, 
a dual AuNprs probe used as a combinatorial platform 
for photoacoustic angiography, localized hyperthermia 
using a subcutaneous, and an orthotopic murine gastric 
carcinoma model has never been reported so far.  
Although it is not a replacement for traditional 
surgery, radiotherapy, or chemotherapy, localized 
hyperthermia has been used in numerous animal 
tumor studies, producing significant synergies with a 
complementary role for treating cancer [14, 15]. Recently, 
Ambrosone et al. reported the use of hyperthermia 
using naked Au triangles that caused hyperthermia 
overexpression of heat shock protein hsp70 with 
concomitant cell necrosis in an invertebrate animal 
model (Hydra vulgaris) [8]. More recently, Han et al. 
reported glucose-functionalized AuNprs for photo-
thermal therapy of cancer tissue [16]. However, the 
impact on the cancer cells and the structure, function, 
growth, and metabolism caused by a series of genetic 
changes using Au triangles in higher organisms 
remains unknown.  
Here, we report that RGD conjugated PEGylated 
(PEG/RGD)-AuNprs are available for tumor angio-
graphy and breast cancer-associated antigen 1 (Brcaa1) 
monoclonal antibody-conjugated PEGylated (PEG/ 
Brcaa1)-AuNprs are used for targeting and in situ 
imaging of gastric carcinoma in orthotopic tumor 
models with high resolution and efficiency rates (Fig. 1). 
In situ photoacoustic imaging allowed for high reso-
lution of blood vessels at the tumor site, with an 
enhancement of the photoacoustic signal in a time- 
dependent manner. This platform is the first proof- 
of-concept, reporting two AuNprs probes used as high 
sensitivity contrasts and therapeutic agents for in situ 
PAI of gastric cancer, in vivo tumor detection, and 
inhibition. These smart and biocompatible PEG/RGD- 
AuNprs and PEG/Brcaa1-AuNprs can be used as 
efficient and safe nanotheranostic platforms for high 
sensitivity in vivo tumor detection, as well as for tumor 
targeting, which results in tumor size reduction and 
increases mice survival after localized hyperthermia 
treatment. 
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2 Experimental  
2.1 Synthesis and characterization of functionalized 
PEGylated AuNprs  
The surfactant-free methods for synthesis and 
characterization of functionalized PEGylated AuNprs 
can be found in our previous publications [7, 9]. 
Briefly, before functionalization, AuNprs were 
washed in deionized (DI) water and suspended in 2- 
(morpholino)ethanesulfonic acid (MES; 0.1 M, pH 6.0) 
solution. 3-(3-Dimethylaminopropyl)-carbodiimide 
(EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) 
were added to 300 μL of the PEGylated AuNpr 
solution in the reactive MES solution (0.1 M, pH = 6) 
and allowed to react for 30 min at room temperature 
with EDC and sulfo-NHS final concentrations of 40 
and 35 mM, respectively. After the reaction, the buffer 
was replaced by phosphate-buffered saline (PBS, pH = 
8.0) and an excess of RGD-4C (GL Biochem Shanghai 
Ltd, China) or 300 μL Brcaa1 [17] monoantibody 
(2 mg/mL) was added and incubated for 3 h at room 
temperature. The resulting PEGylated AuNprs were 
stored in the dark at 4 °C until further use. 
The absorbance spectra of AuNprs, PEG-AuNprs, 
and RGD-PEG-AuNprs were measured by a Varian 
Cary 50 UV–Vis spectrophotometer. The morphology 
of the AuNprs was evaluated using high-resolution 
transmission electron microscopy (TEM, JEOL, JEM- 
2010) and field emission scanning electron microscopy 
(FESEM, Zeiss Ultra5). The photoacoustic signal 
acquisition was performed using 10 replicates at each 
wavelength (680, 700, 710, 808, and 950 nm) in a 
Nexus 128 (Endra Nexus 128, USA) and analyzed by 
OsiriX imaging software (OsiriX Foundation, Genève, 
Switzerland).  
2.2 In vitro study of RGD-PEG-AuNprs 
Human gastric epithelial mucosa cell line, GES-1, and 
human gastric cancer cell line, MGC-803, were used 
as models. GES-1 cells were cultured in a 5% CO2- 
 
Figure 1 AuNprs as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized 
hyperthermia. (a) Schematic illustration of the AuNprs functionalized with PEG and a cyclic RGD peptide (PEG/RGD-AuNprs) and 
their application in photoacoustic angiography and in targeted phototherapy in the tumor vessels. (b) Schematic illustration of the
antibody Brcaa1-AuNprs and their application in in situ photoacoustic imaging of gastric tumors. 
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balanced air incubator at 37 °C  in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin. MGC-803 
cells were cultured in RPMI 1640 medium containing 
10% FBS and 1% penicillin-streptomycin at 37 °C and 
in 5% CO2. GES-1 cells were first cultured to 60% 
confluency before trypsinized to 5,000/well and seeded 
in a 96-well cell culture plate. Cells were incubated 
overnight in a conventional cell culture environment. 
For the MTT assay, cells were incubated with 50, 100, 
150, and 200 μg/mL of naked AuNprs, PEG-AuNprs, 
RGD-PEG-AuNprs, or AuNprs-Brcaa1 particles for 
24 h. The absorbance was read at 570 nm and the cell 
viability was determined from the intensity ratio of 
the treated to non-treated control cells and shown as 
an average ± standard deviation (n = 5). 
For the TEM images, MGC-803 cells were incubated 
with RGD-AuNprs (50 μg/mL Au) for 24 h and collected. 
The cells were treated with 2.5% glutaraldehyde 
phosphate buffer and fixed overnight before being 
rinsed with 0.1 M PBS three times (15 min each), 
incubated in 1% osmium tetroxide for 2 h, and rinsed 
with 0.1 M phosphate three times (15 min each). 
Samples were dehydrated sequentially in 30% and 
50% ethanol for 10 min, 70% ethanol containing 2% 
uranyl acetate, and finally stained overnight. Next, 
the samples were dehydrated in 70% and 90% ethanol 
for 10 min each, followed by incubation in a 90% 
acetone/90% ethanol (1:1 v/v) solution for 15 min and 
rinsed in 90% acetone for 15 min. Finally, the samples 
were rinsed with 100% acetone at room temperature 
three times, embedded with +812 epoxy with pure 
acetone (1:1 v/v) at room temperature for 1–2 h, 
followed by pure acetone +812 epoxy resin (1:2) at 
room temperature for 3–4 h, and finally embedded in 
epoxy resin overnight with 812. The following day, 
the samples were embedded in epoxy resin 2–3 times 
every 4 h. The samples were cured at 37 °C overnight, 
then 45 °C for 12 h, and 60 °C for 48 h. With a microtome 
slice thickness of 70 nm and lead citrate staining, the 
samples were imaged for TEM (JEOL, JEM-2010). 
For cell viability after laser irradiation, MGC-803 
cells were incubated with RGD-AuNprs for 24 h. Then, 
the cells were washed twice with PBS and irradiated 
with 980 nm laser light for 3 min at 2 W/cm2. After 
irradiation, the cells were stained with Trypan Blue. 
The control group was MGC-803 cells without NP 
treatment. 
2.3 Construction of murine gastric cancer models 
All animal experiments were approved by the 
Institutional Animal Care and Use Committee of 
Shanghai Jiao Tong University (NO.SYXK2007-0025). 
Female nude mice (nu/nu, 18 g, and 4 weeks old) 
were purchased from the Shanghai SLAC Laboratory 
Animal Co. Ltd and housed in an SPF grade animal 
center. Subcutaneous gastric cancer (GC) tissues at the 
exponential growth phase loaded in nude mice were 
resected aseptically. Necrotic tissues were cut away, 
and the remaining tumor tissues were scissor-minced 
into pieces around 1–2 mm in diameter in 4 °C Hanks’ 
balanced salt solution and each piece was adjusted to 
30 mg using scissors. Before the surgery, all mice were 
fasting for at least 8 h. Mice were anesthetized with 
5% trichloraldehyde hydrate (4 μL/g weight) and an 
incision was made through the left upper abdominal 
pararectal line and peritoneum. The stomach wall was 
carefully exposed, and a part of the serosal membrane 
(~2 mm in diameter) in the middle of the greater 
curvature of the glandular stomach was mechanically 
scratched with ophthalmic knives. A tumor piece of 
30 mg was then fixed on the injured site of the serosal 
surface with OB glue (Guang Zhou Baiyun Ltd, China). 
The stomach was then returned to the peritoneal 
cavity, and the abdominal wall and skin were closed 
with 9-0 ophthalmic sutures. The mice were kept on a 
warm electric blanket at 37 °C until analepsis and kept 
separately in an SPF environment. 
2.4 In vivo PAI study of murine gastric cancer 
models 
In vivo PAI was accomplished by a PA system (Endra 
Nexus 128, USA) with the excitation laser set at the 
bottom of a hemispherical bowl. For subcutaneous 
tumor models, mice were injected intraperitoneally 
with 5% chloral hydrate (w/v) and supplemented with 
1%–2% isoflurane, an appropriate gas for anesthesia. 
Nude mice with GC xenografts (subcutaneous or 
orthotopic models) were intravenously injected with 
100 μL of 1 mg/mL RGD-AuNprs or Brcaa1-AuNprs, 
respectively. The Nexus 128 system was equipped with 
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high (for subcutaneous xenografts) or low positions 
(for orthotopic xenografts) for image acquisition. The 
following irradiation laser wavelengths were chosen 
to observe the in vivo PA signal of the xenografts: 680, 
700, 710, 808, 950, and 710 nm. Data were collected after 
1, 3, and 6 h. The PA signals, which were received by 
the ultrasonic transducers, were spirally distributed 
on the surface of the bowl before finally directed to 
computational graphic reconstruction. Reconstruction 
of the 2D and 3D PA images was performed by OsiriX 
imaging software (OsiriX Foundation, Switzerland). 
2.5 NIR absorption digital high-definition infrared 
microscopic imaging and localized hyperthermia of 
murine subcutaneous tumor model of gastric cancer 
For in vitro measurements, the photothermal effect of 
AuNprs was evaluated via irradiation by a 980 nm 
laser (LOS-BLD-0980-1.3W-C, Hi-Tech Optoelectronics 
Co., Ltd. China) and read by an oscillometer (34970A, 
Agilent, USA). Briefly, for in vivo applications, a trial 
group (GC xenograft mice transplanted subcutaneous 
tumor models) was injected with 100 μL of 1 mg/mL 
RGD-AuNprs via tail vein. After 2 h, the 980 nm laser 
was applied to irradiate the tumor site and the images 
of temperature variation at the tumor site were 
accomplished by the digital high-definition infrared 
microscopic imaging system (Ying Fu Photoelectric 
Technology Co. Ltd, Shanghai, China). The laser energy 
was 2 W/cm2 (read according to a standard curve, data 
not shown).  
2.6 Computed tomography (CT) imaging 
In order to compare with the PAI, nude mice with GC 
xenografts (subcutaneous or orthotopic models) were 
also intravenously injected with 100 μL of 1 mg/mL 
RGD-AuNprs and Brcaa1-AuNprs and used in CT 
and X-ray imaging. CT imaging (Latheta LCT200, 
Hitachi-Aloka, Japan) was used for in situ imaging 
with the tube voltage of 50 kVp and exposure time  
of 300 ms. For X-ray imaging (Carestream FX PRO, 
KODAK, USA), the exposure time was 15 s.  
2.7 Distribution and pathological analysis of RGD- 
PEG-AuNprs in subcutaneous gastric cancer models 
For in situ models, tumors were removed 24 h after 
the injection of Brcaa1-AuNprs and fixed in 5% 
paraformaldehyde overnight before being embedded 
in paraffin for tissue sections. For immunofluorescence 
staining, Brcaa1 mouse anti-human antibody (1 mg/mL 
concentration of 1:100) was used as the primary 
antibody and FITC-rabbit anti-mouse (Abcam, UK) 
as the secondary antibody (1:1,000).  
For in vivo biodistribution studies, nude mice with 
GC xenografts were intravenously injected with 100 μL 
of 1 mg/mL RGD-AuNprs before being sacrificed at 
24 h and 6 weeks post-injection (n = 3/group). The heart, 
liver, spleen, lungs, kidneys, and tumor sites were 
collected and weighed. The tissues (50 mg) were digested 
with aqua regia under heating. The Au concentration 
in solution was determined by an iCAP 6000 Radial 
(Thermo, USA). 
2.8 Statistical analysis 
Each experiment was repeated three times in duplicate 
if not stated otherwise. The results were presented as 
the mean ± SD. Statistical differences were evaluated 
using the t-test and considered significant at P < 0.05. 
3 Results and discussion 
In this study, antibody (Brcaa1 monoclonal antibody) 
and peptide (RGD) functionalized AuNprs were used 
as a combinatorial methodology for in situ photoacoustic 
imaging, angiography, and localized hyperthermia for 
gastric carcinoma. RGD peptides have been exten-
sively investigated as cell adhesion peptides that are 
recognized by cell-surface receptors, such as integrin 
ανβ3. RGD peptide can mediate cell adhesion and 
proliferation and plays an important role in tumor 
angiogenesis and metastasis, being considerably 
upregulated in the endothelium during angiogenesis. 
Therefore, RGD represents a marker for malignancy 
[18] and has become a useful tool for the targeting of 
drugs and probes for functionalized imaging contrast 
agents [19, 20]. 
Brcaa1 was screened from a large number of clinical 
specimens associated with the breast cancer antigen 
gene. It was also demonstrated to have high expression 
in 65% of gastric cancer cells, and this expression 
increases with the progression of malignancy [17]. 
Therefore, the Brcaa1 monoclonal antibody was 
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prepared and applied to target human gastric cancer 
cells [21, 22]. 
AuNprs coated with PEG-COOH, a cyclic peptide 
RGD-4C (Arg-Gly-Asp bicyclic peptide, 
ACDCRGDCFCG, disulfide bonds), and an antibody 
for Brcaa1 were characterized by TEM and UV–vis– 
NIR spectroscopy extinction. Figure 2(a) represents 
the TEM image of naked AuNprs. A nearly flat shape 
of an equilateral triangle with a side length of about 
110 nm can be observed. UV–vis–NIR spectroscopy 
extinction spectra of naked RGD-conjugated PEGylated 
AuNprs are depicted in Fig. 2(b). Two distinct peaks 
around 980 and 530 nm can be observed with a slightly 
red-shifted peak for RGD-conjugated PEGylated 
AuNprs.  
In order to normalize the AuNprs photoacoustic 
signals as a function of the concentration, the lowest 
concentration of AuNprs was selected as an internal 
reference solution, with an absorbance of approximately 
0.05 OD. A linear relationship (R2 = 0.991) between 
the absorption at 710 nm and the concentration of  
the photoacoustic signal in relation to the AuNprs 
hemispherical photoacoustic detection system is 
represented in Fig. 2(c). 
To evaluate the thermal effects of AuNprs, the tem-
perature of AuNprs in aqueous solution was evaluated 
over time using a 980-nm laser light source (Agilent 
digital thermocouple and logger detection) (Fig. 2(d)). 
Figure 2(d) shows the variation of temperature under 
980 nm laser irradiation near the heating location ~1 cm 
from the area under laser illumination. Six different 
concentrations of AuNprs (0, 5, 10, 30, 75, 150, and 
300 μg/mL) were applied. The temperature of the 
AuNprs solution increases to around 88 °C for the 
300 μg/mL AuNprs under 0.3 W/cm2 irradiation for 
5 min. At a moderate AuNprs concentration of 75 μg/mL, 
the ΔT reached 31 °C. These results clearly demonstrate 
that the prepared AuNprs have substantial thermal 
effects under low laser energy irradiation, which is 
the basis of their application as photoacoustic contrast 
agents and for hyperthermia treatment of cancer- 
diseased cells. 
The cellular uptake of the AuNprs was characterized 
using TEM (Fig. S1 in the Electronic Supplementary 
Material (ESM)) and two-photon microscopy (Fig. S2 
in the ESM). The TEM images show subcellular 
localization of the RGD-conjugated PEGylated AuNprs 
in MGC-803 cells (Fig. S1(a) in the ESM). RGD- 
conjugated PEGylated AuNprs are distributed in the 
cytoplasm within the cell vesicles (Fig. S1(b) in the 
ESM). Under a 746 nm excitation laser, two-photon 
fluorescence microscopy showed that RGD-conjugated  
 
Figure 2 (a) TEM of AuNprs. (b) UV–vis–NIR spectra of AuNprs solution, PEGylated AuNprs, and RGD-AuNprs. (c) Dependence of 
PA signals on the AuNprs concentration. (d) Dependence of temperature on AuNprs concentration under the irradiation time of 5 min at 
0.3 W/cm2. 
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PEGylated AuNprs can easily reach the cytoplasm (in 
24 h) of previously incubated MGC-803 cells (Fig. S2 
in the ESM). White fluorescent dots observed in the 
cytoplasm of the cells indicate the intracellular uptake 
of the RGD-conjugated PEGylated AuNprs, whereas 
actin fibers are stained in red and Brcaa1-FITC in 
green and blue dots (Hoechst staining) indicate the 
nuclei of the cells.  
The cytotoxicity of the antibody/peptide AuNprs 
was evaluated using the GES-1 cell line. An MTT 
assay was performed to assess the cell viability  
using increasing amounts of AuNprs without laser 
irradiation (Figs. S3 and S4 in the ESM). Increasing 
amounts (50, 100, 150, and 200 μg/mL) of PEG-coated, 
RGD-coated PEGylated AuNprs, Brcaa1-antibody- 
conjugated PEGylated-AuNprs, as well as naked 
AuNprs were incubated with 5 × 103 cells for 24 h. The 
Brcaa1-antibody-coated and RGD-coated PEGylated 
AuNprs showed nearly 100% cell viability with 
increasing concentration without light exposure.   
In addition, no noticeable cytotoxicity (<10%) was 
observed for naked AuNprs. 
Hydrodynamic light scattering (DLS) in water and 
zeta-potential data of all AuNprs-conjugates (naked 
AuNprs, PEG-AuNprs, RGD-AuNprs, and Brcaa1- 
antibody-AuNprs) (Fig. S5 in the ESM), as well as the 
conjugation and quantification of Brcaa1 antibody on 
the surface of the nanoprisms (Fig. S6 in the ESM) was 
also performed in order to corroborate appropriate 
functionalization of the studied biomolecules. 
In order to evaluate the cell structural integrity, 
MGC-803 cells incubated with RGD-coated PEGylated 
AuNprs were irradiated under 100 mW, 980 nm laser 
power for 3 min. The cells were stained with Trypan 
Blue and imaged by optical microscopy. Although the 
cell morphology at this magnification remained normal, 
an increase in membrane permeability in response to 
Trypan Blue (vital stain used to selectively color dead 
cells only) due to the thermal effects of NPs was 
observed only for cells incubated with RGD-coated 
PEGylated AuNprs, when compared to control cells 
without exposure (Fig. S7 in the ESM).  
In order to evaluate the full potential of the 
functionalized AuNprs for in vivo tumor targeting 
and angiography, an in vivo murine orthotopic model  
of gastric cancer was built. The tumor accumulation 
was characterized in MGC803 bearing mice by taking 
photoacoustic images after tail-vein administration  
of RGD-coated PEGylated AuNprs at a concentration 
of 1 mg/mL. The best signal to noise ratio at a 
wavelength of 710 nm was selected and scanned. 
Using OsiriX software analysis, tumor vascular imaging 
was achieved via image acquisition for maximum 
density projection (MIP). Figure 3(a) shows in vivo 
photoacoustic images of subcutaneous transplanted 
tumors and sequential photoacoustic MIP frames of 
tumor blood vessels before and 1, 3, and 6 h after 
tail-vein injection of RGD-coated PEGylated AuNprs. 
Using the conventional Nexus 128 system, imaging 
the tumor vasculature and the blood vessels could only 
be achieved through endogenous injection of a contrast 
agent, such as hemoglobin or deoxyhemoglobin. In 
addition, the tumor edges could roughly be imaged 
in the outermost region of the tumor (i.e. closest to 
the skin layer). The interior of the blood vessels was 
not visible. After tail-vein injection of RGD-coated 
PEGylated AuNprs, the blood vessels at the tumor 
site were clearly imaged, with an enhancement of the 
photoacoustic signal in a time-dependent manner 
(Figs. 3(b)–3(d)). In addition, RGD peptide-specific 
targeting of the tumor angiogenesis could be observed  
 
Figure 3 In vivo photoacoustic imaging study of subcutaneous 
transplanted tumors. (a)–(d) Sequential PA MIP frames after tail- 
injection with RGD-AuNprs. (a) Before injection with RGD- 
AuNprs, (b) injection with RGD-AuNprs after 1 h, (c) injection with 
RGD-AuNprs after 3 h, (d) injection with RGD-AuNprs after 6 h. 
Scale bars: 1 mm. 
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using the optoacoustic imaging of solid tumors to 
monitor angiogenesis and cancer progression. In fact, 
4 h after injection, the prepared RGD-conjugated 
PEGylated AuNprs accumulated at the tumor site, as 
observed in the 3D PAI images of the tumors (Fig. S8 
in the ESM). Moreover, the thermal effect of RGD- 
conjugated PEGylated NPs could be exploited to 
treat cancer-diseased cells [23]. 
In order to evaluate the in situ functional targeting 
and imaging of gastric carcinoma, a second mouse 
model and a different functionalization of AuNprs were 
used. A gastric-cancer orthotopic mouse tumor model 
was developed and Brcaa1 antibody-conjugated 
PEGylated AuNprs (PEG/Brcaa1-AuNprs) were pro-
duced. First, the MGC-803 cell line was used to build 
the subcutaneous tumor model in nude mice. After 
the formation of the tumor tissue, the tumor tissue 
stability in nude mice was passaged three more times 
in order to access and insert fresh tumor tissue blocks 
in nude stomach via an OB adhesive construction of 
orthotopic gastric tumor transplantation. The OB glue 
paste technique is commonly used to establish nude 
mouse human gastric cancer orthotopic transplantation 
models. The OB glue paste technique is easy to perform 
and the biological behaviors of the nude mice human 
gastric cancer orthotopic transplantation models 
established with this technique are similar to the natural 
processes of growth and metastasis of human gastric 
cancer [24]. After establishing the orthotopic model, 
the blood supply and stomach tissue can easily be 
built. Rapid tumor growth in mice can be maintained 
for about four weeks. Figures S9(a) and S9(b) in the 
ESM show the orthotopic tumor mass model after four 
weeks, in which the blood supply and tumor volume 
significantly increase compared with the primary 
surgery to establish the tumor model (Fig. S9(a) in  
the ESM). Four weeks after the OB surgery, mice 
were tail-vein injected with PEG/Brcaa1-AuNprs and 
photoacoustic images were taken. Figure 4 and Fig. S10 
in the ESM show the results for the photoacoustic 
imaging of mice without (Fig. 4(a) and Movie S1 in the 
ESM) and with intravenous injection of PEG-AuNprs 
after 24 h (Fig. 4(b) and Movie S2 in the ESM). As 
shown in Fig. 4(a), the MIP of the photoacoustic signal 
was weak and chaotic with a major interference from 
hemoglobin when there was no injection of contrast 
agent. In contrast, when injected with PEG/Brcaa1- 
AuNprs, the tumor image improved significantly and 
imaging of the surface blood vessels was possible 
(Fig. 4(b) and Movie S2 in the ESM). At this time (24 h), 
no signal differences or levels of development could 
be distinguished between the various body organs, 
and therefore, the tumor location could not be 
determined to accomplish functional imaging. 
Nevertheless, 24 h after injection of PEG/Brcaa1- 
AuNprs, a significant difference between blood vessels, 
organs, and the tumor site was observed (Fig. 4(c) 
and Movie S3 in the ESM). Surgical scars (showing 
an “X” shape), surgical nylon thread, and the gastric 
site (Fig. 4(c)) were easily displayed in photoacoustic 
imaging of PEG/Brcaa1-AuNprs treated mice. In 
addition, the signal from the gastric tissue site was more 
intense than the signal of surrounding organs such  
as the liver, proving that the PEG/Brcaa1-AuNprs 
effectively targets the gastric tumor site. 
The shape and appearance of the mouse gastric tissue 
anatomy is depicted in Figs. 4(e) and 4(f). Gastric tumor 
tissues of mice treated with PEG/Brcaa1-AuNprs were 
stained using Brcaa1 immunofluorescent antibody 
only. Figs. 4(g)–4(i) show immunofluorescence staining 
of Brcaa1 in pathological tumor tissue using FITC- 
labeled goat anti-mouse secondary antibody, confirming 
the specificity of the PEG/Brcaa1-AuNprs targeting. 
These data prove that photoacoustic imaging can 
be used to overcome some of the disadvantages (i.e. 
radioactive conditions and poor resolution in soft 
tissues from CT/X-ray, poor resolution with deep 
penetration from NIR fluorescence imaging, or speckles 
of optical coherence tomography) of imaging modalities, 
and penetrate deeper with high-resolution imaging. 
Photoacoustic imaging in cancer detection has been 
mainly focused on melanoma models, subcutaneous 
tumor xenograft transplantation models, or in vitro 
lymphangiography [13]; however, detection is still 
confined to superficial parts of the body. Here,   
we could achieve in situ effective detection of tumor 
targeting with concomitant deep and high-resolution 
photoacoustic imaging of the tumor site. Most impor-
tantly, we could improve the visualization of surface 
acoustic imaging of diseased tissues, thus advancing 
the detection of internal organs of the targeted lesion. 
This method is not only capable of distinguishing the 
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different organs, but also of achieving structural 
imaging of the tumor site and maximizing the signal 
to achieve functional imaging. Our method is now able 
to fully reflect the photoacoustic contrast advantage 
in cancer imaging.  
In order to validate these results, PEG/RGD-coated 
AuNprs were used in X-ray and PEG/Brcaa1-coated 
AuNprs in CT imaging. Owing to its high atomic 
number and its absorption of X-rays, Au is often used 
in X-ray and CT imaging. In fact, many studies have 
shown that targeted Au NPs can increase the resolu-
tion at the tumor site, but with significantly higher 
concentrations of contrast agents. Here, we used 
~5 mg/kg Au in the mouse model, although CT based 
on Au NPs usually requires 40–50 mg/kg Au for in vivo 
tumor imaging [25, 26]. Therefore, PEG/RGD-coated 
AuNprs (1 mg/mL in 100 μL) and PEG/Brcaa1-coated 
AuNprs (1 mg/mL in 100 μL) were intravenously 
injected in mice bearing gastric tumors, and X-ray 
and CT detection was performed. As shown in Fig. 5, 
X-ray imaging of the control group (no NP treatment) 
showed no effect on the tumor site (Fig. 5(a)), whereas 
the X-ray image with 1 mg/mL of PEG/RGD-coated 
AuNprs had a significantly enhanced signal (Fig. 5(b)). 
The same applies for CT imaging, in which PEG/ 
Brcaa1-AuNprs (1 mg/mL in 100 μL) were also 
intravenously injected in mice. The CT image with 
1 mg/mL of PEG/Brcaa1-AuNprs showed no significant 
difference in the in situ gastric portion (Fig. 5(d)) when 
compared to the control group (Fig. 5(c)).  
 
Figure 4 Representative photoacoustic imaging of gastric orthotopic tumor after injection of Brcaa1-AuNprs. (a) No injection of probes.
(b) Photoacoustic imaging of gastric orthotopic tumor with injection of AuNprs after 24 h. (c) In situ targeting photoacoustic imaging 
using intravenously injected PEG/Brcaa1-AuNprs after 48 h. (d) Image of scar and black surgical nylon thread. (e) and (f) Anatomical
images of the localized gastric cancer tumor. (g)–(i) Immunohistochemical staining of tumor section from in situ gastric cancer tumor 
model. (g) DAPI staining of gastric tumor slides. (h) Immunofluorescence staining of Brcaa1 in human gastric tumor. (i) Merged image.
Scale bar: 100 μm. 
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Figure 5 X-ray and micro CT imaging. (a) X-ray image of 
control group (no NP treatment). (b) X-ray image with 1 mg/mL 
of PEG/RGD-coated AuNprs. (c) CT image of control group. (d) 
CT image with 1 mg/mL of Brcaa1-AuNprs. 
These data show that using a single-dose injection 
probe, photoacoustic imaging in a subcutaneous tumor 
model using PEG/RGD-coated AuNprs (see Fig. 3) 
and an in situ tumor model using PEG/Brcaa1-coated 
AuNprs (see Fig. 4) can achieve better sensitivity and 
resolution results than conventional X-ray and CT 
imaging with the same dose of Au NPs. 
In order to evaluate the localized hyperthermia 
effect mediated by the functionalized AuNprs, a 
subcutaneous gastric-cancer xenograft mice model was 
used. Mice were injected with 100 μL of 1 mg/mL 
PEG/RGD-coated AuNprs via tail-vein injection. A 
980 nm NIR laser and a high-definition digital infrared 
thermal imaging system were used for thermal imaging 
2 h after injection (Fig. 6). The tumor was exposed  
to the 980 nm laser at 2 h post-injection (0.3 W/cm2, 
5 min). Figure 6(a) represents the temperature variation 
at the tumor site from 0 to 5 min after laser irradiation. 
Figure 6(a1) represents a thermal image of the repre-
sentative MGC-803 tumor-bearing mouse before the 
laser is turned on, when the skin surface temperature 
is only 25.9 °C. After irradiation for 100 (Fig. 6(a2)),  
150 (Fig. 6(a3)), and 200 s (Fig. 6(a4)), the average 
temperatures at the tumor site after radiation are 40.7, 
57.6, and 71.1 °C, respectively. Figure 6(b) shows the 
hyperthermia in vivo assay measuring temperature 
variation in the control (no NP exposure) and experi-
mental (injection of 100 μL of 1 mg/mL PEG/RGD- 
coated AuNprs) groups. In each image, the average 
of seven temperature measurement points was taken 
(six points and one point in the center of the 
circumference selection). The temperature at the tumor 
site in the experimental group (PEG/RGD-coated 
AuNprs) reached a peak of 75 °C after 200 s of exposure, 
showing significant thermal effects when compared 
to the control group, where the highest temperature 
is 30 °C (Figs. 6(b) and 6(c)). Figures 6(c1) and 6(c2) 
represent the local tumor morphology after localized 
hyperthermia of the control and experimental groups, 
respectively. The tissue without treatment (Fig. 6(c1)) 
had a normal appearance of intact skin, whereas the 
tissue after irradiation of the tumor exhibited a dark 
color (Fig. 6(c2)). Comparative results from photo-
acoustic imaging experiments showed deformation 
of the blood vessels surrounding the tumor tissue 
after hyperthermia therapy with PEG/RGD-coated 
AuNprs (Fig. 5(d)), while the control group at the 
same irradiation dose showed no significant change 
in tumor blood vessels (Fig. 6(d)). These results confirm 
the high efficiency of PEG/RGD-AuNprs and PEG/ 
Brcaa1-AuNprs as a combinatorial-targeted therapy 
in thermal imaging and therapy.  
The contribution to mice survival from localized 
hyperthermia effects at the tumor site using PEG/ 
RGD-AuNprs was assessed by monitoring survival 
after 150 days. Animals treated with PEG/RGD-AuNprs 
survived significantly longer (Fig. 7(a)) than the control 
groups before and after therapy and PEG/RGD- 
AuNprs group without therapy. The trends in pro-
longed survival from PEG/RGD-AuNprs after therapy 
treatment indicate that the observed survival extension 
of more than 85% could be attributed to the destruction 
of gastric cancer cells via localized hyperthermia.  
Moreover, we hypothesized that the increase in 
mice survival using PEG/RGD-AuNprs after therapy 
would also enhance the likelihood of observing a 
tumor size reduction. Therefore, monitoring the change 
in tumor size as a function of time after treatment with 
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PEG/RGD-AuNprs associated with laser application 
revealed a significant decrease in tumor growth (P < 
0.005) at 27 days post AuNprs treatment (Fig. 7(b)) with 
a single-dose injection. After 35 days, animals treated 
with PEG/RGD-AuNprs after hyperthermia therapy 
show a tumor size of 22.1% ± 7.6%, compared to 100% 
± 15.1% and 80.1% ± 14.6% for control groups before 
and after treatment, respectively, and 90.0% ± 9.6% 
for PEG/RGD-AuNprs before therapy.  
The improved outcome in gastric tumor-bearing 
mice receiving PEG/RGD-AuNprs treatment strongly 
supports the extraordinary potential of these NPs as 
adjuvant agents to anticancer therapies. 
The safety and biodistribution of PEG/RGD-AuNprs 
was confirmed by ex vivo organ inductively coupled 
plasma mass spectrometry (ICP-MS) for 6 h and    
14 days after injection of the probes. The results show 
that 6 h after injection, PEG/RGD-AuNprs were mainly 
accumulated in the liver, kidney, lung, and tumor. 
After 14 days, the Au content decreased in most of the 
tissues and organs, especially in the heart and kidney 
(Fig. 7(c)). 
To validate the safety assessment, 14 days after 
injection of PEG/RGD-AuNprs, organs were harvested 
from mice and H&E stained for routine pathological 
analysis (Fig. 7(d)). H&E staining shows that in vivo 
 
Figure 6 In vivo photothermal therapy study using intravenously injected RGD-AuNprs. (a) Thermal images of representative MGC-803
tumor-bearing mouse exposed to 980 nm laser (0.3 W/cm2) for 3 min at 1 h post-injection of RGD-AuNprs. (b) Tumor heating curves of 
the PBS and RGD-AuNprs injected mice groups. (c) Localized tumor images of mice after 3 min exposure to laser. (c1): control group, 
(c2): experimental group. (d) Photoacoustic image of angiography for control group injected with PBS and for experimental group injected
with PEG/RGD-coated AuNprs monitoring before and after tumor therapy. 
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administration of PEG/RGD-AuNprs did not damage 
to several organs (i.e. lung, liver, kidney, spleen, or 
heart) when compared to the control group (without 
AuNpr administration). The lungs showed a clear and 
complete alveolar structure, a uniform distribution of 
the nucleus and cytoplasm was observed in liver 
tissue, the kidney tubules and glomeruli showed no 
obvious lesions, and the spleen showed normal white 
and red pulp distribution. Moreover, a normal cardiac 
morphology and intracellular free grainy was observed 
in the heart. 
4 Conclusions 
Traditional imaging techniques are frequently limited 
by narrow penetration, low sensitivity, low specificity, 
and poor spatial resolution. Hybrid modalities such as 
optoacoustic imaging, an emerging molecular imaging 
modality, have greatly contributed to improving most 
of these limitations. 
In summary, we developed a hybrid approach for 
both photoacoustic angiography and localized hyper-
thermia using antibody/peptide AuNprs in a subcu-
taneous and an orthotopic murine gastric carcinoma 
model. This system proved to be highly efficient for 
in situ photoacoustic imaging, with high-resolution of 
blood vessels at the tumor site and an enhancement 
of the photoacoustic signal coupled to localized 
hyperthermia. With a single-dose injection, these smart 
antibody/peptide AuNprs are responsible for an 
extensive tumor size reduction and increase in mice 
survival after localized hyperthermia treatment.  
This is the first proof-of-concept using two AuNprs 
probes as high sensitivity contrasts and therapeutic 
 
Figure 7 Therapeutic outcome following treatment with PEG/RGD AuNprs in subcutaneous transplanted gastric tumors. (a) Kaplan-
Meier survival curves during 150 days of control mice (no NP treatment) and for PEG/RGD AuNprs before and after localized
hyperthermia therapy. (b) Relative tumor size in mice bearing gastric tumor xenografts treated with PEG/RGD AuNprs before and after
localized hyperthermia therapy and compared to control groups. (c) ICP-MS of Au content at 6 h and 14 days after injection with 
PEG/RGD-AuNprs (n = 3). (d) H&E stained tissue sections of the organs (i.e. lung, liver, kidney, spleen, heart) collected from mice 20
days after intravenous injection of a single dose of PEG/RGD-AuNprs. Bar: 50 μm. 
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agents for in vivo tumor detection and inhibition, which 
can be used as an efficient and safe nanotheranostic 
platform. Taken together, the results reported herein 
establish the mechanism of action of AuNprs in both 
imaging and targeting approaches, as well as the 
relationship between hyperthermia time, intensity, 
and efficacy in an in vivo mouse model, which will 
translate in a very meaningful way to cancer clinical 
research.  
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